TERF2IP

Across TCGA pan-cancer cohorts, TERF2IP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TERF2IP data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TERF2IP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TERF2IP expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LSCC are the cancer types where TERF2IP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.546	0.289	.002	33	view →
GBM	OS	Tertile	All	0.670	0.308	<.001	22	view →
LSCC	OS	Tertile	III,IV	0.591	0.986	.017	18	view →
HNSC	DFS	Median	All	0.895	0.412	.021	12	view →
LUAD	OS	Quartile	All	0.900	0.315	.002	11	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TERF2IP–PDAC (DFS)

Open the PDAC breakdown →